Literature DB >> 15489657

Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors.

Klaus J Busam1, Urvi Mujumdar, Amanda J Hummer, Jennifer Nobrega, William G Hawkins, Daniel G Coit, Mary S Brady.   

Abstract

Desmoplastic melanoma (DM) is a variant of melanoma, which may be confused with nonmelanocytic benign or malignant spindle cell proliferations. The histologic hallmark of DM is the presence of fusiform melanocytes dispersed in a prominent collagenous stroma. Phenotypic heterogeneity of DM is underrecognized. Desmoplasia may be prominent throughout the entire tumor ("pure" DM) or represent a portion of an otherwise nondesmoplastic melanoma ("combined" DM). We reviewed melanomas with desmoplasia from 92 patients seen at a single institution between 1980 and 2002. Fifty-five of the tumors were pure DM. Thirty-seven were classified as combined. Mean follow-up of patients was 46 months for those alive at the last follow-up. Univariate analysis of clinical and pathologic parameters revealed four significant variables for disease-free survival: Clark level (IV vs. V; P = 0.005), DM subtype (pure vs. combined; P = 0.01), tumor mitotic rate (<1, 1-4, >4 mitoses/mm; P = 0.01), and tumor thickness (<1 mm, 1-4 mm, >4 mm; P = 0.02). Only histologic subtype (P = 0.02) and Clark level (P = 0.05) were independently significant by Cox regression analysis. Our results indicate that distinguishing pure from combined forms of DM is clinically relevant for prognosis (pure forms being associated with longer disease-specific survival). Failure to make this distinction may account for conflicting reports in the literature on the biologic behavior and prognosis of DM.

Entities:  

Mesh:

Year:  2004        PMID: 15489657     DOI: 10.1097/01.pas.0000141391.91677.a4

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  30 in total

1.  Melanoma subtypes demonstrate distinct PD-L1 expression profiles.

Authors:  Genevieve J Kaunitz; Tricia R Cottrell; Mohammed Lilo; Valliammai Muthappan; Jessica Esandrio; Sneha Berry; Haiying Xu; Aleksandra Ogurtsova; Robert A Anders; Alexander H Fischer; Stefan Kraft; Meg R Gerstenblith; Cheryl L Thompson; Kord Honda; Jonathan D Cuda; Charles G Eberhart; James T Handa; Evan J Lipson; Janis M Taube
Journal:  Lab Invest       Date:  2017-07-24       Impact factor: 5.662

Review 2.  [Histological spectrum of malignant melanoma].

Authors:  T Brenn
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

3.  Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma.

Authors:  Daniel E Oliver; Kirtesh R Patel; Jeffrey Switchenko; Douglas Parker; David H Lawson; Keith A Delman; Ragini R Kudchadkar; Mohammad K Khan
Journal:  Melanoma Res       Date:  2016-02       Impact factor: 3.599

4.  Desmoplastic melanoma with sarcomatoid dedifferentiation.

Authors:  Maija Kiuru; Gregory McDermott; Michael Berger; Allan C Halpern; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

5.  Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.

Authors:  Anne M Stowman; Alexandra W Hickman; Ileana S Mauldin; Adela Mahmutovic; Alejandro A Gru; Craig L Slingluff
Journal:  Melanoma Res       Date:  2018-06       Impact factor: 3.599

6.  NF1 Mutations Are Common in Desmoplastic Melanoma.

Authors:  Thomas Wiesner; Maija Kiuru; Sasinya N Scott; Maria Arcila; Allan C Halpern; Travis Hollmann; Michael F Berger; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

7.  Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Authors:  Ludmila Danilova; Hao Wang; Joel Sunshine; Genevieve J Kaunitz; Tricia R Cottrell; Haiying Xu; Jessica Esandrio; Robert A Anders; Leslie Cope; Drew M Pardoll; Charles G Drake; Janis M Taube
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

8.  Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?

Authors:  Dale Han; Jonathan S Zager; Daohai Yu; Xiuhua Zhao; Brooke Walls; Suroosh S Marzban; Nikhil G Rao; Vernon K Sondak; Jane L Messina
Journal:  Ann Surg Oncol       Date:  2013-02-07       Impact factor: 5.344

Review 9.  [Hypopigmented melanocytic tumors with spindle cells. A review].

Authors:  M Hantschke
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

10.  Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value?

Authors:  Patrick Scanlon; Jaiying Tian; Judy Zhong; Ines Silva; Richard Shapiro; Anna Pavlick; Russell Berman; Iman Osman; Farbod Darvishian
Journal:  Hum Pathol       Date:  2014-04-18       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.